Nexara Health — Health Canada Drug Establishment Licence #3-002896

Comparator supply for NCT07291037

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Sponsor: AstraZeneca (INDUSTRY). Phase: PHASE3. Status: Recruiting. Countries: United States, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Poland, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, Vietnam. Last update posted 2026-09-04.

Registry record: https://clinicaltrials.gov/study/NCT07291037.

Canadian-labelled docetaxel

4 marketed Canadian product(s) from 4 manufacturer(s) contain docetaxel. Available strengths: 10 MG, 20 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.

What we supply

Frequently asked questions

Can Nexara supply Canadian-labelled docetaxel as a trial comparator?

Yes. We source Canadian-marketed docetaxel under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT07291037.

What documentation comes with each shipment?

Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.

How long does comparator supply take?

Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.

Request comparator quote

Request comparator quote or call +1-431-588-9055.

Related pages